Novel <i>MYBL1</i> Gene Rearrangements with Recurrent <i>MYBL1–NFIB</i> Fusions in Salivary Adenoid Cystic Carcinomas Lacking t(6;9) Translocations

Yoshitsugu Mitani(The University of Texas MD Anderson Cancer Center), Bin Liu(The University of Texas MD Anderson Cancer Center), Pulivarthi H. Rao(Baylor College of Medicine), Vishnupriya J. Borra(Baylor College of Medicine), Mark Zafereo(The University of Texas MD Anderson Cancer Center), Randal S. Weber(The University of Texas MD Anderson Cancer Center), Merrill S. Kies(The University of Texas MD Anderson Cancer Center), Guillermina Lozano(The University of Texas MD Anderson Cancer Center), P. Andrew Futreal(The University of Texas MD Anderson Cancer Center), Carlos Caulı́n(The University of Texas MD Anderson Cancer Center), Adel K. El‐Naggar(The University of Texas MD Anderson Cancer Center)
Clinical Cancer Research
December 2, 2015
Cited by 200Open Access
Full Text

Abstract

PURPOSE: Adenoid cystic carcinoma (ACC) is an indolent salivary gland malignancy, characterized by t(6;9) translocations and MYB-NFIB gene fusions in approximately 50% of the tumors. The genetic alterations underlying t(6;9)-negative and t(6;9)-positive/MYB-NFIB fusion-negative ACC remain unknown. To uncover the genetic alterations in ACC lacking the canonical translocation and fusion transcript and identify new abnormalities in translocation positive tumors. EXPERIMENTAL DESIGN: We performed whole-genome sequencing in 21 salivary ACCs and conducted targeted molecular analyses in a validation set (81 patients). Microarray gene-expression data were also analyzed to explore the biologic differences between fusion positive and negative tumors. RESULTS: We identified a novel MYBL1-NFIB gene fusion as a result of t(8;9) translocation and multiple rearrangements in the MYBL1 gene in 35% of the t(6;9)-negative ACCs. All MYBL1 alterations involved deletion of the C-terminal negative regulatory domain and were associated with high MYBL1 expression. Reciprocal MYB and MYBL1 expression was consistently found in ACCs. In addition, 5'-NFIB fusions that did not involve MYB/MYBL1 genes were identified in a subset of t(6;9)-positive/fusion-negative tumors. We also delineated distinct gene-expression profiles in ACCs associated with the length of the MYB or MYBL1 fusions, suggesting a biologic importance of the C-terminal part of these fusions. CONCLUSIONS: Our study defines new molecular subclasses of ACC characterized by MYBL1 rearrangements and 5'-NFIB gene fusions.


Related Papers

No related papers found

Powered by citation graph analysis